Certivos verified
Tyco Bio
Manufacturer QC
- Purity
- 98.56%
- Method
- HPLC + MS
W6MAQSUAXA9G→ View certificate
In stock
PT-141
10mg · Single vial · Lyophilized powder
Single vial49.99CAD
Sexual health research
PT-141 is a synthetic melanocortin receptor agonist compound, studied in neurological pathways related to sexual function.
- Investigated in hypoactive sexual desire research literature, including studies focused on premenopausal women
- Referenced in melanocortin receptor pharmacology research
- Studied for central nervous system pathways involved in sexual response
Order
1
- Dose
- 10mg
- Pack size
- Single vial
- Form
- Lyophilized powder
- Storage
- 2–8°C
In vitro laboratory research use only · Not for human or veterinary use · Batch documented · Third-party tested · Ships from Canada
§ Verification — Batch 20260720-01
Certificates are issued and hosted by Certivos.
§ Research
Research · PT-141
Overview
PT-141 (bremelanotide) is a synthetic cyclic seven-residue analog of alpha-melanocyte-stimulating hormone (alpha-MSH), closed by a lactam bridge, and is an active metabolite of melanotan II, from which it differs by a C-terminal free acid in place of an amide. It was developed by Palatin Technologies and was approved for clinical use in the United States in 2019. It is used as a reference agonist in research on central melanocortin signaling. Its cyclic structure confers resistance to proteolytic degradation relative to the linear native hormone, supporting its use in in vivo pharmacology studies.
Mechanism of action
Acts as a non-selective agonist at melanocortin receptors, with highest relevance at the melanocortin 4 receptor (MC4R) and activity at MC1R, MC3R, and MC5R. These are Gs-coupled G-protein-coupled receptors that increase intracellular cAMP upon activation. MC4R is expressed in hypothalamic nuclei including the medial preoptic area, where receptor activation is proposed to modulate dopaminergic signaling in circuits governing sexual motivation. Unlike PDE5 inhibitors, its effects are mediated centrally rather than through peripheral vascular nitric oxide-cGMP pathways. Activity at MC1R on melanocytes accounts for reported pigmentation changes.
Key research findings
- 01
Preclinical rodent studies characterize MC4R-dependent effects on solicitation and appetitive sexual behaviors, abolished by melanocortin receptor antagonism.
- 02
Early clinical studies (2006) characterized effects on subjective sexual response endpoints in premenopausal participants with sexual arousal disorder.
- 03
Two phase 3 randomized controlled trials (RECONNECT) characterized desire and distress endpoints, supporting the 2019 regulatory review.
- 04
Ambulatory blood pressure studies characterized transient increases in systolic and diastolic pressure, and clinical data document nausea and focal hyperpigmentation as common adverse events.
Published references
Bremelanotide: First Approval
An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist
The information above is derived from published preclinical and clinical research. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.